These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1164 related articles for article (PubMed ID: 24504054)

  • 21. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.
    Eiber M; Takei T; Souvatzoglou M; Mayerhoefer ME; Fürst S; Gaertner FC; Loeffelbein DJ; Rummeny EJ; Ziegler SI; Schwaiger M; Beer AJ
    J Nucl Med; 2014 Feb; 55(2):191-7. PubMed ID: 24309383
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-small cell lung cancer staging: efficacy comparison of integrated PET/CT versus 3.0-T whole-body MR imaging.
    Yi CA; Shin KM; Lee KS; Kim BT; Kim H; Kwon OJ; Choi JY; Chung MJ
    Radiology; 2008 Aug; 248(2):632-42. PubMed ID: 18552311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The application of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer].
    Xu HF; Liu Y; Zhang JH; Zhou RS; Zhou FH; Yuan MH
    Zhonghua Jie He He Hu Xi Za Zhi; 2005 Feb; 28(2):108-11. PubMed ID: 15854393
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
    Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
    Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Locoregional tumour evaluation of squamous cell carcinoma in the head and neck area: a comparison between MRI, PET/CT and integrated PET/MRI.
    Schaarschmidt BM; Heusch P; Buchbender C; Ruhlmann M; Bergmann C; Ruhlmann V; Schlamann M; Antoch G; Forsting M; Wetter A
    Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):92-102. PubMed ID: 26243264
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative Performance of ¹⁸F-FDG PET/MRI and ¹⁸F-FDG PET/CT in Detection and Characterization of Pulmonary Lesions in 121 Oncologic Patients.
    Sawicki LM; Grueneisen J; Buchbender C; Schaarschmidt BM; Gomez B; Ruhlmann V; Wetter A; Umutlu L; Antoch G; Heusch P
    J Nucl Med; 2016 Apr; 57(4):582-6. PubMed ID: 26742715
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mediastinal lymph nodes staging by 18F-FDG PET/CT for early stage non-small cell lung cancer: a multicenter study.
    Li X; Zhang H; Xing L; Ma H; Xie P; Zhang L; Xu X; Yue J; Sun X; Hu X; Chen M; Xu W; Chen L; Yu J
    Radiother Oncol; 2012 Feb; 102(2):246-50. PubMed ID: 22100657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients.
    Vansteenkiste JF; Stroobants SG; De Leyn PR; Dupont PJ; Bogaert J; Maes A; Deneffe GJ; Nackaerts KL; Verschakelen JA; Lerut TE; Mortelmans LA; Demedts MG
    J Clin Oncol; 1998 Jun; 16(6):2142-9. PubMed ID: 9626214
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Primary tumor SUVmax measured on (18)F-FDG PET-CT correlates with histologic grade and pathologic stage in non-small cell lung cancer].
    Zhao SJ; Wu N; Zheng R; Liu Y; Zhang WJ; Liang Y; Zhang H; Li XM
    Zhonghua Zhong Liu Za Zhi; 2013 Oct; 35(10):754-7. PubMed ID: 24378097
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Breast cancer staging in a single session: whole-body PET/CT mammography.
    Heusner TA; Kuemmel S; Umutlu L; Koeninger A; Freudenberg LS; Hauth EA; Kimmig KR; Forsting M; Bockisch A; Antoch G
    J Nucl Med; 2008 Aug; 49(8):1215-22. PubMed ID: 18632831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of Standardized Uptake Values in Normal Structures Between PET/CT and PET/MRI in a Tertiary Pediatric Hospital: A Prospective Study.
    Lyons K; Seghers V; Sorensen JI; Zhang W; Paldino MJ; Krishnamurthy R; Rohren EM
    AJR Am J Roentgenol; 2015 Nov; 205(5):1094-101. PubMed ID: 26496558
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical significance of dual-time-point 18F-FDG PET imaging in resectable non-small cell lung cancer.
    Shimizu K; Okita R; Saisho S; Yukawa T; Maeda A; Nojima Y; Nakata M
    Ann Nucl Med; 2015 Dec; 29(10):854-60. PubMed ID: 26254228
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Functional imaging of lung cancer using dual energy CT: how does iodine related attenuation correlate with standardized uptake value of 18FDG-PET-CT?
    Schmid-Bindert G; Henzler T; Chu TQ; Meyer M; Nance JW; Schoepf UJ; Dinter DJ; Apfaltrer P; Krissak R; Manegold C; Schoenberg SO; Fink C
    Eur Radiol; 2012 Jan; 22(1):93-103. PubMed ID: 21822784
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk factors for predicting the occult nodal metastasis in T1-2N0M0 NSCLC patients staged by PET/CT: potential value in the clinic.
    Li L; Ren S; Zhang Y; Guan Y; Zhao J; Liu J; Wang Q; Chen G; Chen H; Xiang J; Fu X
    Lung Cancer; 2013 Aug; 81(2):213-7. PubMed ID: 23664030
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Limited predictive value of dual-time-point F-18 FDG PET/CT for evaluation of pathologic N1 status in NSCLC patients.
    Kim SJ; Kim YK; Kim IJ; Kim YD; Lee MK
    Clin Nucl Med; 2011 Jun; 36(6):434-9. PubMed ID: 21552019
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Integrated FDG-PET/CT does not make invasive staging of the intrathoracic lymph nodes in non-small cell lung cancer redundant: a prospective study.
    Tournoy KG; Maddens S; Gosselin R; Van Maele G; van Meerbeeck JP; Kelles A
    Thorax; 2007 Aug; 62(8):696-701. PubMed ID: 17687098
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Significance of dual-time-point 18F-FDG PET imaging in evaluation of hilar and mediastinal lymph node metastasis in non-small-cell lung cancer].
    Hu M; Yu JM; Liu NB; Liu LP; Guo HB; Yang GR; Zhang PL; Xu XQ
    Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):306-9. PubMed ID: 18788639
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic accuracy of whole-body PET/MRI and whole-body PET/CT for TNM staging in oncology.
    Heusch P; Nensa F; Schaarschmidt B; Sivanesapillai R; Beiderwellen K; Gomez B; Köhler J; Reis H; Ruhlmann V; Buchbender C
    Eur J Nucl Med Mol Imaging; 2015 Jan; 42(1):42-8. PubMed ID: 25112399
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
    Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
    Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Utility of 18F-FDG PET/CT in the diagnosis and staging of extramammary Paget's disease.
    Tian Y; Wu HB; Li DL; Li HS; Zhou WL; Wang QS
    Nucl Med Commun; 2015 Sep; 36(9):892-7. PubMed ID: 25932540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 59.